Imunon Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Imunon Q2 EPS USD -2.15
Imunon Inc expected to post a loss of $4.74 a share - Earnings Preview
Brief: Imunon Announces First Patient Dosed In Phase 3 Ovation 3 Study Of Imnn-001 In Newly Diagnosed Advanced Ovarian Cancer
Brief: Imunon Submits Plan In Consultation With Exchange To Ensure Compliance With Nasdaq's Listing Requirement, Anticipates Additional Compliance Period
Brief: Imunon - Terminates CFO David Gaiero's Service Agreement
Imunon Inc reports results for the quarter ended March 31 - Earnings Summary
Imunon Inc expected to post a loss of 35 cents a share - Earnings Preview
Imunon Inc reports results for the quarter ended December 31 - Earnings Summary
Imunon Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Imunon Announces Translational Data From Phase 1/2 Ovation 2 Study Of Imnn-001 In Advanced Ovarian Cancer
Brief: Imunon Announces Positive Cmc Meeting With FDA For Imnn-001 In Treatment Of Advanced Ovarian Cancer
Brief: IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA
Imunon Inc reports results for the quarter ended in September 30 - Earnings Summary
Imunon Inc expected to post a loss of 40 cents a share - Earnings Preview
Imunon Inc reports results for the quarter ended in June - Earnings Summary
Imunon Inc expected to post a loss of 54 cents a share - Earnings Preview
Imunon Inc expected to post a loss of 54 cents a share - Earnings Preview
Brief: Imunon Announces Database Lock For Phase 2 Ovation 2 Study With IMNN-001 In Advanced Ovarian Cancer